title: Integration of noninvasive prenatal prediction of fetal blood group into clinical prenatal care.
abstract: Incompatibility of red blood cell blood group antigens between a pregnant woman and her fetus can cause maternal immunization and, consequently, hemolytic disease of the fetus and newborn. Noninvasive prenatal testing of cell-free fetal DNA can be used to assess the risk of hemolytic disease of the fetus and newborn to fetuses of immunized women. Prediction of the fetal RhD type has been very successful and is now integrated into clinical practice to assist in the management of the pregnancies of RhD immunized women. In addition, noninvasive prediction of the fetal RhD type can be applied to guide targeted prenatal prophylaxis, thus avoiding unnecessary exposure to anti-D in pregnant women. The analytical aspect of noninvasive fetal RHD typing is very robust and accurate, and its routine utilization has demonstrated high sensitivities for fetal RHD detection. A high compliance with administering anti-D is essential for obtaining a clinical effect. Noninvasive fetal typing of RHC/c, RHE/e, and KEL may become more widely used in the future.
authors.affiliation: Laboratory of Blood Genetics, Department of Clinical Immunology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
authors.forename: Frederik Banch
authors.initials: FB
authors.lastname: Clausen
mesh_terms: D001789:Blood Group Antigens / Q000032:analysis*; D004899:Erythroblastosis, Fetal / Q000517:prevention & control; D005260:Female; D005312:Fetal Blood / Q000737:chemistry*; D005333:Fetus; D006801:Humans; D007231:Infant, Newborn; D016133:Polymerase Chain Reaction; D011247:Pregnancy; D011295:Prenatal Care; D011296:Prenatal Diagnosis / Q000379:methods*
chemical_list: D001789:Blood Group Antigens